266 related articles for article (PubMed ID: 3807263)
1. [Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].
Harenberg J; Giese C; Knödler A; Zimmermann R; Schettler G
Klin Wochenschr; 1986 Nov; 64(22):1171-5. PubMed ID: 3807263
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of low molecular weight heparin by protamine chloride in vivo.
Harenberg J; Gnasso A; de Vries JX; Zimmermann R; Augustin J
Thromb Res; 1985 Apr; 38(1):11-20. PubMed ID: 4002198
[TBL] [Abstract][Full Text] [Related]
3. Does protamine chloride neutralize low molecular weight heparin sufficiently?
Gram J; Mercker S; Bruhn HD
Thromb Res; 1988 Dec; 52(5):353-9. PubMed ID: 2851882
[TBL] [Abstract][Full Text] [Related]
4. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.
Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M
Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291
[TBL] [Abstract][Full Text] [Related]
5. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride.
Andrassy K; Eschenfelder V; Weber E
Thromb Res; 1994 Jan; 73(2):85-93. PubMed ID: 8171416
[TBL] [Abstract][Full Text] [Related]
7. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
[TBL] [Abstract][Full Text] [Related]
8. In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine.
Doutremépuich C; Bonini F; Toulemonde F; Bertrand H; Bayrou B; Quilichini R
Semin Thromb Hemost; 1985 Jul; 11(3):318-22. PubMed ID: 4048954
[TBL] [Abstract][Full Text] [Related]
9. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
10. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments.
Racanelli A; Fareed J; Walenga JM; Coyne E
Semin Thromb Hemost; 1985 Apr; 11(2):176-89. PubMed ID: 4035365
[No Abstract] [Full Text] [Related]
12. Comparative effects of heparin and LMW heparin on hemostasis.
Hirsh J; Buchanan MR
Thromb Res Suppl; 1991; 14():11-7. PubMed ID: 1658966
[TBL] [Abstract][Full Text] [Related]
13. Interaction of heparin and protamine in presence of overdosage: in vitro study.
Hanke AA; Severloh I; Flöricke F; Weber CF; Lang T
Asian Cardiovasc Thorac Ann; 2021 Jan; 29(1):5-9. PubMed ID: 32854516
[TBL] [Abstract][Full Text] [Related]
14. Andexanet Alfa, the Possible Alternative to Protamine for Reversal of Unfractionated Heparin.
Maneno JN; Ness GL
Ann Pharmacother; 2021 Feb; 55(2):261-264. PubMed ID: 32667214
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
Diness V; Ostergaard PB
Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
[TBL] [Abstract][Full Text] [Related]
16. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
17. Studies on the anticoagulant action of heparin, protamine, and Polybrene in the activation of factor IX.
Shanberge JN; Fukui H
J Lab Clin Med; 1967 Jun; 69(6):927-37. PubMed ID: 6025496
[No Abstract] [Full Text] [Related]
18. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
19. Andexanet Alfa Neutralizes the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin Almost as Protamine Sulfate.
Siddiqui F; Hoppensteadt D; Jeske W; Ramacciotti E; Tafur A; Fareed J
Clin Appl Thromb Hemost; 2024; 30():10760296241247558. PubMed ID: 38656136
[TBL] [Abstract][Full Text] [Related]
20. Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis.
Silver PJ; Broughton R; Bouthillier J; Quinn TA; Wallace AM; Weishaar RE
Thromb Res; 1998 Aug; 91(3):143-50. PubMed ID: 9733158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
